Nivolumab-based treatment (N+AVD) improves progression-free survival in advanced-stage Hodgkin’s lymphoma patients compared ...

New data from Barinthus Bio's HBV003 trial has demonstrated durable HBsAG loss in participants with chronic hepatitis B.

Princeton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a ...

(Alliance News) - Scancell Holdings PLC on Monday reported positive data from an ongoing trial on patients receiving a treatment combination for advanced melanoma, a skin cancer.

Moreover, Arce highlighted the additional benefits observed when nivolumab was added to the treatment combination of imdusiran and VTP-300. This combination further reduced HBsAg levels, enhancing the ...

I am proposing that all companies currently engaged in developing biosimilars join hands with their regulatory and scientific ...

LOUISVILLE, Ky. -- More than half of patients with newly diagnosed metastatic kidney cancer responded to a novel drug ...

During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in ...

Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...